Sarepta Therapeutics (SRPT) Stock: Buy, Sell, or Hold?
SRPT - Sarepta Therapeutics,, Inc. Common Stock
$17.57
-0.65 (-3.57%)
▼
5d:
-4.46%
30d:
-17.63%
90d:
-8.87%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 02, 2026
30d
Get Alerted When SRPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SRPT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SRPT shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$4.71
Based on -20.2% avg growth
INTRINSIC VALUE TODAY
$2.92
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SRPT is currently trading at $17.57, which is considered oversold relative to its 30-day fair value range of $18.75 to $21.70. The stock's valuation (Forward PE: 7.3) is in line with its historical norms (6.8). At these levels, the market is pricing in 2.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SRPT is in a strong downtrend. The price is currently testing key support at $17.52. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $21.73 (+23.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SRPT is in a strong downtrend. The price is currently testing key support at $17.52. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $21.73 (+23.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$18.75 -
$21.70
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.7%
Protect Your Profits
Holding SRPT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 23.7% below Wall St target ($21.73)
- NEUTRAL: Market pricing in 2.1% annual earnings growth - fairly valued
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$18.75 -
$21.70
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$17.52
Resistance Level
$21.19
Current Trend
Strong Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.29
Wall Street Target
$21.73
(+23.7%)
Revenue Growth (YoY)
-34.3%
Earnings Growth (YoY)
2663.8%
Profit Margin
-6.9%
Valuation Premium vs History
+2.1% premium
PE vs Historical
7.3 vs 6.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.1%
(market-implied from PE analysis)
1-Year Target
$17.94
(+2%)
2-Year Target
$18.32
(+4%)
3-Year Target
$18.70
(+6%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
PE COMPRESSION
$17.45
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: -44.4%)
$35.86
(+104%)
Base:
(SPY PE: 7.3, Growth: -44.4%)
$12.81
(-27%)
Bear:
(PE: 6.2, Growth: -44.4%)
$10.89
(-38%)
Share & Embed Analysis
Last updated: October 02, 2026 1:54 AM ET
Data refreshes hourly during market hours. Next update: 2:54 AM
Data refreshes hourly during market hours. Next update: 2:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SRPT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 59 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 73 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 44 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 62 BUY |
Advanced SRPT Option Strategies
Professional options setups generated by AI based on today's SRPT price and gamma walls.
